Answers are grounded in this paper and cite their sources.
Randomized trial demonstrates superior HbA1c reduction in type 2 diabetes with HR17031, suggesting improved treatment outcomes.
Introduction and Objective: HR17031 is a once-daily, novel combination of basal insulin analogue (insulin sudelidec) and GLP-1 receptor agonist (noiiglutide). This randomized, treat to target Phase 3 trial evaluated the efficacy and safety of HR17031 vs iGlar in pts with T2D uncontrolled on Met with/without one other OAD. Methods: 401 Pts with T2D (HbA1c 7.5%-11.0%; previous Met ± another OAD) were randomized (1:1) to open-label once-daily HR17031 or iGlar for 26-week (wk) treatment. Then all pts entered 26-wk extension treatment with the iGlar group switching to HR17031. Primary outcome was change in HbA1c after 26 wks. Results: At 26 wks, HR17031 was superior to iGlar in HbA1c reductions from baseline (LSM: −1.85% vs −1.06%). More pts achieved HbA1c target <7%, <6.5% and <7.0% without weight gain in HR17031(66.8%, 50.5% and 20.3%) than iGlar (38.7%, 17.6% and 9.0%). HR17031 treatment was associated with less weight gain (LSM: 1.50 vs 2.79kg) and more FPG reduction than iGlar (LSM: -3.34 vs -2.83 mmol/L). The insulin dose of HR17031 was lower than iGlar (LSM: 23.0 vs 30.4 U/d). The incidence of Grade 2/3 hypoglycemic events was similar (2.0% vs 4.0%). Common HR17031-induced gastrointestinal adverse events were diarrhea (8.0%), abdominal distension (7.0%) and nausea (6.0%). Conclusion: HR17031 demonstrated superior efficacy in pts with T2D uncontrolled on OADs than iGlar with favorable safety profile. Disclosure L. Ji: None. L. Zhang: None. D. Liu: None. J. Liu: None. L. Li: None. Z. Zeng: None. X. Dong: Employee; Current; Jiangsu Hengrui Pharmaceuticals Co., Ltd. R. Li: Employee; Current; Jiangsu Hengrui Pharmaceuticals Co., Ltd. X. Wu: Employee; Current; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Z. Ye: Employee; Current; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Funding Jiangsu Hengrui Pharmaceuticals Co., Ltd.
No takes yet. Share an insight, caveat, or question.
JI et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: